Rigel Pharmaceuticals PEG Ratio

The latest PEG ratio for RIGL is -5.01. That is above the Healthcare sector average of -5.81. Investors often review this figure alongside Rigel Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, RIGL currently prints -5.01 for PEG ratio, while the sector average sits near -5.81. That is roughly 13.7% above the sector mean. Large gaps often invite a closer look at Rigel Pharmaceuticals's growth, margins, and balance sheet.

A PEG ratio of -5.01 for Rigel Pharmaceuticals is not 'good' or 'bad' on its own. Compare it with the peer average (-5.81) and with RIGL's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting RIGL's PEG ratio (-5.01), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Rigel Pharmaceuticals's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.